Somewhere today, an ICU survivor is leaving the hospital. They survived septic shock. Respiratory failure. Multiple traumatic injuries. They are grateful to be alive.
What they do not know is that the research designed to help them recover more safely at home may never be completed.
In mid-July, the Agency for Healthcare Research and Quality (AHRQ) began notifying researchers across the country that dozens of active research grants would be terminated. As of early August, AcademyHealth reports that 111 grants had been canceled, affecting $136.3 million in committed federal funding. Among them was an approximately $2 million grant awarded to Dr. Leslie P. Scheunemann, an associate professor of medicine at the University of Pittsburgh. Her study sought to improve one of the most vulnerable moments in medicine: the transition from the intensive care unit to home.
Leaving the ICU is not the end of critical illness. For many patients, it is the beginning of an entirely different struggle. Survivors frequently experience profound muscle weakness, cognitive impairment, anxiety, depression, and post-traumatic stress. Many cannot return to work. Many are readmitted to the hospital. Families suddenly become caregivers with little preparation for the challenges ahead. We have a name for this constellation of problems, post-intensive care syndrome, but naming a disease is not the same as solving it.
Real physician voices, twice a week
Free, and one click to unsubscribe.
We still have much to learn about how to help these patients recover. That is precisely why studies like Dr. Scheunemann’s exist. This was not an untested idea scribbled onto the back of an envelope. It was a peer-reviewed, federally funded research project that had survived rigorous scientific evaluation. Experts concluded that the question was important, the methods were sound, and the work deserved public investment.
The cancellation of one grant might appear insignificant in the context of a federal budget. But Dr. Scheunemann’s study was far from an isolated case. Across more than a hundred terminated projects, each asked a different question. Each represented years of planning, institutional investment, research staff, patient participation, and scientific promise. More importantly, each represented patients waiting for better answers.
Many people are familiar with the National Institutes of Health but know less about AHRQ. Unlike agencies that primarily fund the discovery of new drugs or basic science, AHRQ focuses on improving how health care is delivered. Its research asks practical questions. How do we reduce medical errors? How do we improve patient safety? How do we help patients navigate complex transitions of care? How do we provide higher-quality care at lower cost? These questions rarely make headlines. Yet they affect every physician, every hospital, and every patient.
Health services research often lacks the glamour of a breakthrough cancer drug or a revolutionary gene therapy. But safer discharges, fewer readmissions, better communication, and improved recovery after critical illness save lives just as surely as new medications do. When active studies are terminated before completion, the loss extends far beyond the investigators. Patients lose opportunities to benefit from discoveries that may never be made. Clinicians lose evidence that could have informed better care. Early-career physician-scientists lose years of work, momentum, and often the very foundation upon which their independent research careers were being built. Taxpayers lose the value of investments that had already been made. And science loses something even more important: answers.
Every administration has the right to establish research priorities. Budgets are finite. But there is a difference between deciding not to fund a future proposal and terminating an active, peer-reviewed study already underway. When ongoing research is halted without publicly available project-specific scientific justification, confidence in the research enterprise is weakened. Scientists begin to wonder whether peer review still offers meaningful protection. Young investigators question whether years of effort can disappear overnight. Patients may ask whether the studies they volunteered to join will ever fulfill their promise.
Transparency is essential. If an active federally funded research project is terminated, the scientific community and the public deserve to know why. Was the methodology flawed? Were there ethical concerns? Did safety issues emerge? Or was the decision based solely on shifting administrative priorities? Those are very different explanations, and they deserve to be distinguished.
Medicine advances because we ask difficult questions and allow science to answer them. When those questions are silenced before the answers emerge, it is not universities that suffer the greatest loss. It is the patients who may never benefit from knowledge that was within our reach.
Timothy Lesaca is a psychiatrist in private practice at New Directions Mental Health in Pittsburgh, Pennsylvania, with more than forty years of experience treating children, adolescents, and adults across outpatient, inpatient, and community mental health settings. He has published in peer-reviewed and professional venues including the Patient Experience Journal, Psychiatric Times, the Allegheny County Medical Society Bulletin, and other clinical journals, with work addressing topics such as open-access scheduling, Landau-Kleffner syndrome, physician suicide, and the dynamics of contemporary medical practice. His recent writing examines issues of identity, ethical complexity, and patient–clinician relationships in modern health care. Additional information about his clinical practice and professional work is available on his website, timothylesacamd.com. His professional profile also appears on his ResearchGate profile, where further publications and details may be found.
